News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

A Biotech Binary Event Playbook: How To Play Clovis Oncology (CLVS) And Tesaro (TSRO) Ahead Of Label Decision



8/9/2017 8:45:38 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Morgan Stanley said in a note Tuesday it would be buyers of Clovis Oncology Inc ahead of the Lynparza label decision.

AstraZeneca plc (ADR) 's Lynparza is a poly polymerase, or PARP, inhibitor indicated for use as a monotherapy in patients with suspected deleterious germline BRCA mutated advanced ovarian cancer, who have been treated with three or more prior lines of chemotherapy.

The treatment candidate was given priority review status by the FDA in March 2017, which would mean a PDUFA action date some time in the third quarter.

Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES